Immatics (NASDAQ:IMTXW – Get Free Report)’s stock price dropped 3.7% during mid-day trading on Thursday . The stock traded as low as $2.87 and last traded at $2.89. Approximately 1,002 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 7,851 shares. The stock had previously closed at $3.00.
Immatics Stock Performance
The business’s 50-day moving average price is $2.80 and its two-hundred day moving average price is $3.08.
About Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Read More
- Five stocks we like better than Immatics
- The Significance of Brokerage Rankings in Stock Selection
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Why Invest in 5G? How to Invest in 5G Stocks
- MarketBeat Week in Review – 6/24 – 6/28
- Airline Stocks – Top Airline Stocks to Buy Now
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.
